Investors Urged to Act in Class Action Against Capricor Inc.
Important Class Action Notice for Capricor Therapeutics, Inc.
The Gross Law Firm has issued an important notification for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding a recent class action lawsuit. The notice is aimed specifically at those investors who acquired shares during the noted class period.
Details of the Class Period
Shareholders who purchased shares of CAPR between specific dates are encouraged to get in touch with the law firm, as this can potentially lead to a lead plaintiff appointment. This appointment is not a requirement for participating in any recovery from the class action.
Key Allegations in the Complaint
The complaint outlines serious allegations against the defendants. It claims that they misled investors regarding Capricor's lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Investors were provided with overly optimistic information regarding the Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA).
While affirmative statements were made about Capricor's potential to secure the BLA, there were also substantial omissions. Specifically, the defendants allegedly concealed crucial adverse information related to the safety and effectiveness data derived from the Phase 2 HOPE-2 trial of deramiocel.
On July 11, 2025, Capricor announced that it had received a Complete Response Letter (CRL) from the FDA, which reversed any previously optimistic outlook. The CRL indicated that the application did not fulfill the statutory requirements for demonstrating effectiveness and called for additional clinical information.
Market Reaction to the FDA Announcement
This unfavorable news led to a significant decline in the stock price of Capricor. On July 10, 2025, shares closed at $11.40 but dwindled down to $7.64 just a day later following the announcement, prompting many investors to reevaluate their positions.
Registration Deadline for Claims
Shareholders must be proactive, as the deadline for registering in this class action is September 15, 2025. It's crucial to act promptly to have a chance at recovery.
Next Steps for Involved Shareholders
For those registering who purchased shares of CAPR within the designated timeframe, there will be the added benefit of monitoring through portfolio software that provides updates on the progress of the case. This initiative requires no costs or obligations for participants.
Why Choose The Gross Law Firm?
The Gross Law Firm is known for its commitment to protecting the rights of investors facing deceit and mishandled business practices. Their focus is on pursuing legal action against corporations that fail to adhere to ethical and responsible business methods.
This law firm aims to recover losses sustained by investors due to misleading statements or critical omissions that inflated stock prices artificially.
Contact Information
The Gross Law Firm can be reached at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class action about?
The class action pertains to allegations that Capricor misled investors about the prospects of its drug candidate, deramiocel.
When did the class period occur?
The class period lasts from October 9, 2024, to July 10, 2025.
What can I do if I invested in CAPR shares?
If you purchased shares during the class period, consider registering to be part of the class action.
How can I contact The Gross Law Firm?
You can contact them via phone at (646) 453-8903.
Is there a cost to participate in the class action?
No, there is no cost or obligation to participate in this class action.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.